Summary
No FDA-label–specific claims for DORYX/Doryx MPC were provided in the prompt beyond general statements; most AI claims cannot be verified as supported or contradicted by the supplied label excerpts, so label alignment cannot be established.
Category Scores
Accurate Statements
Unsupported Statements
Doryx MPC is a brand of doxycycline made using MPC (modified particle coating) technology.
The supplied label excerpts describe DORYX capsules as specially coated pellets in a delayed-release formulation, but do not mention MPC/modified particle coating technology.
Doryx MPC is used to treat bacterial infections that are susceptible to doxycycline.
The label excerpt provided gives general guidance to use DORYX to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria, but the AI claim uses a specific product/indication phrasing that is not explicitly stated or mapped to a specific labeled indication in the provided text.
Doryx MPC is taken by mouth.
The provided dosage section includes multiple 'by mouth' instructions for doxycycline/DORYX, but the AI statement refers to 'Doryx MPC' specifically; the label excerpts provided do not confirm the identity/name mapping between 'Doryx MPC' and the labeled product 'DORYX Capsules.'
The dosing schedule for Doryx MPC depends on the specific infection and the patient’s age and clinical situation.
The label excerpt provides specific dosing schedules by age/weight and by infection severity, but the AI claim is a generalization that is not explicitly stated as such.
Common doxycycline-class side effects include stomach upset, nausea, and heartburn.
The adverse reactions list includes nausea (and other GI effects), but 'heartburn' and 'common' are not explicitly supported by the provided label text.
Tetracycline antibiotics can cause esophageal irritation if taken without enough water.
The label recommends adequate amounts of fluid with capsule/tablet forms to reduce risk of esophageal irritation and ulceration, but the AI claim is phrased as a specific causation scenario ('if taken without enough water') rather than an explicit label condition.
Tetracycline antibiotics can cause esophageal irritation if the patient lies down soon after taking a dose.
The label notes most reported esophagitis/esophageal ulceration cases occurred in patients who took medications immediately before going to bed, but it does not state a general 'lies down soon after taking a dose' rule.
Get medical help urgently for reactions such as swelling of the face/lips, trouble breathing, or severe rash.
The label includes hypersensitivity reactions such as angioneurotic edema and anaphylaxis, but 'face/lips swelling, trouble breathing, or severe rash' and the instruction to seek urgent help are not explicitly provided in the provided excerpts.
Tetracycline antibiotics (including doxycycline) are often taken by swallowing with a full glass of water.
The label recommends adequate amounts of fluid; it does not specify 'full glass of water' in the general capsule/tablet administration guidance. (An applesauce administration section mentions a 'cool 8-ounce glass of water,' but the AI generalization is not label-exact.)
Tetracycline antibiotics (including doxycycline) are often taken by avoiding lying down right after taking the dose.
The label references timing relative to going to bed for reported esophageal injuries, but does not state an explicit 'avoid lying down right after taking' instruction.
These steps help reduce the risk of esophagus irritation.
The label supports that adequate fluid reduces risk of esophageal irritation/ulceration, but it does not explicitly support the combined 'steps' as stated (full glass + avoiding lying down) as a set.
Doxycycline products can interact with medicines and supplements that bind in the gut.
The label supports specific absorption impairments (antacids with aluminum/calcium/magnesium, iron-containing preparations, and bismuth subsalicylate), but does not use or support the broad 'bind in the gut' concept.
Doxycycline doses need to be separated from antacids containing aluminum and magnesium.
The label states absorption is impaired by antacids containing aluminum, calcium, or magnesium; it does not explicitly state a 'separation' instruction or timing.
Doxycycline doses need to be separated from calcium, iron, and magnesium supplements.
The label states absorption is impaired by antacids containing calcium or magnesium and by iron-containing preparations; it does not provide a 'separated from' regimen/timing.
Doxycycline doses need to be separated from bismuth and some other GI products.
The label states absorption is impaired by bismuth subsalicylate, but does not support 'some other GI products' nor a 'separated from' instruction.
DrugPatentWatch.com tracks approvals and patent events for patent and exclusivity status.
This is not a prescribing-information claim and is not supported by the supplied FDA label excerpts.
The strength of Doryx MPC can vary and dosing instructions vary by infection.
The supplied label excerpts provide specific dosing regimens for doxycycline/DORYX and mention dosage varies by age/weight/infection severity and specific conditions, but do not state that 'strength' of DORYX varies; additionally 'Doryx MPC' is not defined in the provided label.
Contradictions
Low
AI Statement
—
Label Reference
Important Omissions
Exact, label-consistent dosing regimens, durations, and pediatric/weight thresholds for the specific AI claim being evaluated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most issues are verification gaps (unsupported generalizations or name/technology mismatch) rather than clear contradictions in the provided excerpts; however, multiple administration/interaction instructions are not label-exact (e.g., 'full glass', 'avoid lying down right after', 'separated from' timing), which could affect safe use if relied upon as prescriptive guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Enough Label Mapping
Primary Issue
AI claims reference 'Doryx MPC' and MPC technology, but the supplied label excerpts are for 'DORYX Capsules' and do not establish that identity or the MPC concept; many administration/interaction statements are generalized and not explicitly supported with label-exact instructions (e.g., 'full glass', 'separation' timing, 'avoid lying down right after').
Suggested Improvement
Re-evaluate using label-exact product identity (confirm 'Doryx MPC' corresponds to labeled 'DORYX Capsules') and only state instructions that are directly supported in the provided label text (e.g., 'administration of adequate amounts of fluid... to reduce risk of esophageal irritation and ulceration' and specific interaction impairments: antacids with aluminum/calcium/magnesium, iron, and bismuth subsalicylate).